International Journal of Academic Health and Medical Research (IJAHMR)
ISSN: 2643-9824
Vol. 7 Issue 7, July - 2023, Pages: 1-13

Role of Gold Nanoparticles in Enhancing Radiotherapy

Basim A. Almayahi[1, 2], Siti F. Abdul Sani[2], Maha A. Alkhudhari[3], Hairul A. Tajuddin[4]

[1]Department of Physics, Faculty of Science, University of Kufa, Najaf, Iraq
[2]Department of Physics, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia
[3]Department of Biology, Faculty of Science, University of Kufa, Najaf, Iraq
[4]Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia
Corresponding Author: basim.almayahi@uokufa.edu.iq

Abstract: *Gold nanoparticles have gained significant attention in the field of cancer therapy due to their unique properties and potential to enhance radiotherapy. This review provides an overview of the mechanisms by which gold nanoparticles enhance radiotherapy, including increased radiation absorption, generation of secondary low-energy electrons, dose enhancement effects, and modulation of the tumor microenvironment. The selective targeting and localization of gold nanoparticles in tumor tissues are discussed, highlighting the importance of surface modifications and functionalization. Furthermore, the utilization of gold nanoparticles in imaging techniques and treatment monitoring is explored, emphasizing their optical and photothermal properties. Preclinical studies using in vitro and in vivo models demonstrate the enhanced radiotherapy effects of gold nanoparticles. The ongoing clinical trials and translational research are summarized to assess the safety and efficacy of gold nanoparticle-enhanced radiotherapy in human subjects. The potential impact on cancer treatment and patient outcomes is discussed, along with the challenges and future perspectives in optimizing gold nanoparticle properties, standardizing protocols, addressing safety concerns, and integrating with other treatment modalities. In conclusion, gold nanoparticle-enhanced radiotherapy holds great promise in cancer treatment and further research is needed to fully exploit its potential and translate it into clinical practice.*

Keywords: Gold nanoparticles, radiotherapy enhancement, cancer treatment, targeted delivery, imaging and monitoring

I. Introduction

Radiotherapy plays a pivotal role in the treatment of cancer, offering a localized approach to destroy malignant cells and reduce tumor size. However, conventional radiotherapy techniques face challenges in effectively targeting cancer cells while sparing surrounding healthy tissues [1]. This has led to the exploration of novel strategies to enhance the efficacy of radiotherapy and improve treatment outcomes. One such approach involves the use of gold nanoparticles, which have garnered significant attention for their unique properties and potential to enhance the effects of radiation [2].

Gold nanoparticles, typically ranging in size from 1 to 100 nanometers, possess remarkable physicochemical characteristics that make them well-suited for biomedical applications. They exhibit high atomic numbers, exceptional stability, and tunable surface properties, making them attractive candidates for therapeutic interventions. In the context of radiotherapy, gold nanoparticles have emerged as promising agents to augment the effects of radiation and improve its selectivity towards cancer cells [3].

The mechanisms by which gold nanoparticles enhance radiotherapy are multifaceted. Firstly, their high atomic number enables efficient absorption of X-rays or other ionizing radiation, leading to increased radiation dose deposition in the tumor region [4-6]. This augmented radiation absorption provides a localized boost to the therapeutic effect within cancer cells while minimizing damage to healthy tissues. Additionally, gold nanoparticles can generate secondary low-energy electrons when exposed to radiation, creating a cascade of interactions that inflict further damage on cancer cells, ultimately leading to enhanced cell death.
Moreover, gold nanoparticles possess inherent radiosensitizing properties. They can induce the production of reactive oxygen species (ROS) and cause DNA damage within cancer cells, intensifying their vulnerability to radiation-induced cytotoxicity. Furthermore, gold nanoparticles have the ability to modulate the tumor microenvironment, influencing factors such as angiogenesis and hypoxia, which can significantly impact the response to radiotherapy.
In addition to their therapeutic potential, gold nanoparticles offer imaging capabilities that facilitate treatment monitoring and personalized adjustments. Their unique optical and photothermal properties enable their detection and tracking within the body using imaging techniques like computed tomography (CT), magnetic resonance imaging (MRI), or photoacoustic imaging (PAI). This real-time visualization of nanoparticle distribution assists in ensuring accurate targeting, optimizing treatment plans, and assessing treatment response.

While the role of gold nanoparticles in enhancing radiotherapy holds great promise, it is an area of active research and development. Preclinical studies utilizing in vitro experiments and animal models have shown encouraging results, demonstrating the ability of gold nanoparticles to enhance the effects of radiation. Moreover, ongoing clinical trials are exploring the safety, efficacy, and treatment outcomes of gold nanoparticle-enhanced radiotherapy in human subjects.
This comprehensive exploration of gold nanoparticles' role in enhancing radiotherapy aims to shed light on the potential benefits and challenges associated with this emerging field. By harnessing the unique properties of gold nanoparticles, researchers and

clinicians are paving the way for improved cancer treatment strategies that may lead to enhanced therapeutic outcomes and improved quality of life for patients. The aim of the study is to investigate and understand the potential benefits of using gold nanoparticles in combination with radiotherapy for enhancing cancer treatment outcomes. By assessing the efficacy of gold nanoparticles in enhancing the effects of radiation therapy, the study aims to determine their ability to increase radiation absorption, deliver higher doses to tumor tissues, and improve the overall therapeutic response. Additionally, the study seeks to unravel the underlying mechanisms through which gold nanoparticles enhance radiotherapy, including their interactions with radiation, generation of secondary low-energy electrons, induction of DNA damage, and modulation of the tumor microenvironment. Furthermore, the study aims to evaluate the targeting and localization of gold nanoparticles, examining strategies for specific accumulation in cancer cells while minimizing uptake in healthy cells. Safety and toxicity considerations are also crucial aspects to be explored, ensuring the overall biocompatibility and long-term effects of gold nanoparticle-enhanced radiotherapy. Lastly, the study aims to explore the potential for personalized treatment approaches and imaging applications, leveraging the unique properties of gold nanoparticles to monitor treatment response and enable tailored adjustments for improved outcomes. By addressing these objectives, the study aims to contribute to the advancement of cancer treatment strategies and potentially pave the way for more effective and personalized therapeutic interventions.

II. Mechanisms of Gold Nanoparticles in Enhancing Radiotherapy:

A. Increased radiation absorption by gold nanoparticles:
Gold nanoparticles possess a high atomic number, which enables them to efficiently absorb X-rays or other forms of ionizing radiation. Due to their small size and surface modifications, they can accumulate preferentially in tumor tissues. This leads to an increased concentration of gold nanoparticles within the tumor, allowing for enhanced absorption of radiation and localized dose deposition.

B. Generation of secondary low-energy electrons:
When exposed to ionizing radiation, gold nanoparticles can interact with the radiation and generate secondary low-energy electrons through a process called the photoelectric effect. These secondary electrons have shorter ranges and deposit their energy more locally, thereby increasing the likelihood of damaging cancer cells in the vicinity of the nanoparticles.

C. Dose enhancement effect and increased cell death:
The presence of gold nanoparticles in the tumor region enhances the dose of radiation delivered to cancer cells. This increased radiation dose, often referred to as the dose enhancement effect, leads to amplified cellular damage and an enhanced therapeutic response. The secondary low-energy electrons generated by the interaction of radiation with gold nanoparticles contribute to this dose enhancement effect, resulting in increased cell death within the tumor.

D. Radiosensitization through ROS generation and DNA damage:
Gold nanoparticles can act as radiosensitizers by promoting the generation of reactive oxygen species (ROS) when exposed to radiation. ROS can cause oxidative stress and induce DNA damage within cancer cells, rendering them more susceptible to the cytotoxic effects of radiation. This synergistic effect between gold nanoparticles and radiation leads to enhanced radiosensitivity and increased cancer cell death.

E. Modulation of the tumor microenvironment:
Gold nanoparticles have the ability to modulate the tumor microenvironment, which can impact the response to radiotherapy. They can influence factors such as angiogenesis (formation of new blood vessels) and hypoxia (low oxygen levels) within the tumor. By altering these microenvironmental characteristics, gold nanoparticles can enhance the efficacy of radiation therapy. For example, they can normalize tumor blood vessels, improve oxygenation, and overcome hypoxic conditions, thereby sensitizing cancer cells to radiation.

These mechanisms collectively contribute to the enhanced therapeutic effects of gold nanoparticle-enhanced radiotherapy. By increasing radiation absorption, generating secondary low-energy electrons, promoting dose enhancement, inducing DNA damage through ROS generation, and modulating the tumor microenvironment, gold nanoparticles play a crucial role in improving the efficacy of radiotherapy and increasing cancer cell death within the tumor site [5].

III. Tumor Targeting and Localization:

A. Surface modifications and functionalization of gold nanoparticles:
To achieve effective tumor targeting and localization, surface modifications and functionalization of gold nanoparticles are employed. Various strategies can be employed to modify the surface of gold nanoparticles, including the attachment of specific

ligands, antibodies, peptides, or aptamers. These modifications can impart targeting properties to the nanoparticles, enabling them to selectively recognize and bind to specific receptors or biomarkers present on the surface of cancer cells.

B. Selective accumulation in cancer cells or tumor tissues:
Gold nanoparticles can selectively accumulate in cancer cells or tumor tissues due to their unique properties and surface modifications. This selective accumulation can be attributed to the enhanced permeability and retention (EPR) effect, which is a phenomenon where nanoparticles preferentially accumulate in tumor tissues due to the leaky vasculature and impaired lymphatic drainage of tumors. Additionally, the surface modifications of gold nanoparticles, such as the attachment of targeting ligands, enable specific recognition and binding to cancer cells, further enhancing their accumulation within the tumor site.

C. Minimizing uptake in healthy cells:
While the primary objective is to target and deliver gold nanoparticles to cancer cells or tumor tissues, minimizing uptake in healthy cells is crucial to ensure the selectivity and safety of the treatment. To achieve this, several strategies can be employed. The surface modifications and functionalization of gold nanoparticles can be designed to specifically recognize and bind to receptors or biomarkers that are overexpressed or unique to cancer cells. This selective binding reduces the uptake of gold nanoparticles by healthy cells, minimizing potential off-target effects. Additionally, the size, shape, and surface charge of gold nanoparticles can be optimized to minimize non-specific interactions with healthy cells and tissues, further enhancing their specificity towards cancer cells.

By employing surface modifications, functionalization, and optimizing the properties of gold nanoparticles, researchers can enhance their tumor targeting and localization capabilities. This selective accumulation within cancer cells or tumor tissues while minimizing uptake in healthy cells is essential for maximizing the therapeutic benefits of gold nanoparticle-enhanced radiotherapy and minimizing potential side effects.

IV. Imaging and Treatment Monitoring:

A. Optical and photothermal properties of gold nanoparticles:
Gold nanoparticles possess unique optical and photothermal properties that make them valuable for imaging applications. They exhibit strong light absorption and scattering properties in the visible and near-infrared (NIR) regions of the electromagnetic spectrum. This property enables their detection and visualization using various imaging techniques, making gold nanoparticles excellent contrast agents for imaging purposes. Additionally, gold nanoparticles can convert absorbed light energy into heat through a process known as photothermal conversion, which can be utilized for targeted therapies and imaging applications [7].

B. Utilization in imaging techniques (CT, MRI, PAI):
Gold nanoparticles can be utilized in different imaging modalities to visualize their distribution and assess treatment response. These include computed tomography (CT), magnetic resonance imaging (MRI), and photoacoustic imaging (PAI). In CT imaging, gold nanoparticles can enhance the contrast due to their high X-ray absorption, allowing for improved visualization of tumor sites. In MRI, gold nanoparticles can alter the local magnetic field, leading to changes in relaxation times and providing enhanced contrast in the images [7, 8]. In PAI, gold nanoparticles can absorb laser energy and generate acoustic signals, allowing for non-invasive imaging of deep tissues with high resolution and sensitivity.

C. Real-time monitoring of nanoparticle distribution and accumulation:
One of the significant advantages of using gold nanoparticles in imaging is the ability to monitor their distribution and accumulation in real-time. By incorporating gold nanoparticles into the tumor site, imaging techniques can track their movement, accumulation, and clearance within the body. This real-time monitoring provides valuable information about the nanoparticle distribution, allowing clinicians to assess the effectiveness of the treatment, optimize treatment plans, and make personalized adjustments if necessary. It also facilitates the evaluation of nanoparticle uptake in tumor tissues versus healthy tissues, ensuring accurate targeting and minimizing off-target effects.

By leveraging the optical and photothermal properties of gold nanoparticles, researchers can employ various imaging techniques to visualize their distribution and monitor the treatment response. This real-time monitoring enables clinicians to assess the efficacy of gold nanoparticle-enhanced radiotherapy, optimize treatment parameters, and make informed decisions regarding personalized treatment approaches. The imaging capabilities of gold nanoparticles contribute to the development of more precise and targeted cancer therapies, improving overall treatment outcomes [9].

V. Preclinical Studies and Experimental Models:

A. In vitro studies demonstrating enhanced radiotherapy effects:

In vitro studies are conducted using cell culture models to assess the enhanced radiotherapy effects of gold nanoparticles. Cancer cells are exposed to radiation in the presence or absence of gold nanoparticles, and various parameters such as cell viability, clonogenic survival, DNA damage, and apoptosis are evaluated. These studies provide valuable insights into the dose enhancement effect, radiosensitization, and increased cell death resulting from the combination of gold nanoparticles and radiation [10]. In vitro studies also help elucidate the underlying mechanisms responsible for the enhanced therapeutic effects observed [4, 5].

B. In vivo studies using animal models:

In vivo studies using animal models are crucial to evaluate the efficacy and safety of gold nanoparticle-enhanced radiotherapy in a more physiologically relevant setting. Animal models, such as mice or rats, are implanted with tumor xenografts or genetically engineered tumors [11, 12]. Gold nanoparticles are administered to the animals, and radiation therapy is subsequently delivered to the tumor site. Tumor growth inhibition, survival rates, and histopathological analyses are performed to assess the therapeutic efficacy. These studies provide important data on the tumor targeting and localization capabilities of gold nanoparticles, as well as their overall impact on treatment outcomes.

C. Evaluation of nanoparticle delivery and targeting efficacy:

In preclinical studies, the delivery and targeting efficacy of gold nanoparticles are evaluated. This involves assessing the accumulation of nanoparticles in tumor tissues versus healthy tissues, evaluating the biodistribution and clearance pathways, and determining the extent of nanoparticle uptake by cancer cells. Techniques such as imaging (CT, MRI, or PAI), histology, and molecular analyses are used to track the nanoparticle distribution and evaluate their localization within the tumor microenvironment. These studies help validate the targeting strategies and optimize the delivery protocols for gold nanoparticles in combination with radiotherapy [13].

Preclinical studies and experimental models play a critical role in providing valuable data on the efficacy, safety, and mechanisms of gold nanoparticle-enhanced radiotherapy [4, 5]. In vitro studies allow for controlled investigations of cellular responses, while in vivo studies provide insights into the therapeutic effects in complex biological systems. Additionally, the evaluation of nanoparticle delivery and targeting efficacy helps refine the strategies for optimal nanoparticle accumulation within the tumor site. Collectively, these preclinical studies lay the foundation for the translation of gold nanoparticle-enhanced radiotherapy into clinical applications, facilitating the development of more effective and targeted cancer treatment approaches.

VI. Clinical Trials and Translational Research:

A. Overview of ongoing clinical trials:

Clinical trials are essential for evaluating the safety, efficacy, and feasibility of gold nanoparticle-enhanced radiotherapy in human subjects. Ongoing clinical trials provide valuable insights into the translation of this treatment approach from preclinical studies to real-world applications. These trials involve recruiting patients with specific types of cancer and administering gold nanoparticles in combination with radiotherapy. The trials may vary in terms of the specific cancer types, treatment protocols, and outcome measures being assessed [14, 15].

B. Assessment of safety and efficacy in human subjects:

Clinical trials focus on assessing the safety and efficacy of gold nanoparticle-enhanced radiotherapy in human subjects. Safety assessments involve monitoring and documenting any adverse effects or toxicities associated with the treatment. This includes evaluating short-term side effects during and after treatment, as well as potential long-term effects. Efficacy assessments involve measuring treatment response, tumor control rates, and overall survival outcomes. Imaging techniques, such as CT scans or MRI, may be used to monitor tumor size and response to treatment.

C. Treatment outcomes and patient responses:

Clinical trials aim to evaluate treatment outcomes and patient responses to gold nanoparticle-enhanced radiotherapy. This includes assessing tumor regression or stabilization, progression-free survival rates, and overall survival rates. Patient-reported outcomes, such as quality of life measures, may also be evaluated to determine the impact of the treatment on the patients' well-being. These outcomes and responses provide valuable information about the effectiveness and benefits of gold nanoparticle-enhanced radiotherapy in real-world clinical settings.

Translational research, which bridges the gap between preclinical studies and clinical applications, plays a crucial role in advancing the understanding and implementation of gold nanoparticle-enhanced radiotherapy. Clinical trials provide the opportunity to validate the findings from preclinical studies, assess the safety and efficacy of the treatment in human subjects, and gain insights into its real-

world impact on patient outcomes. The results of these trials contribute to the growing body of evidence, guiding the refinement of treatment protocols, optimizing patient selection criteria, and informing clinical practice for the use of gold nanoparticle-enhanced radiotherapy in cancer treatment.

VII. Future Perspectives and Challenges:

A. Optimization of gold nanoparticle properties for maximum enhancement:

Future research efforts should focus on optimizing the properties of gold nanoparticles to maximize their enhancement of radiotherapy. This includes exploring different sizes, shapes, surface coatings, and targeting ligands to enhance tumor targeting and radiation absorption. Additionally, the development of multifunctional nanoparticles that can simultaneously enhance imaging, drug delivery, and therapeutic effects holds promise for improving treatment outcomes [16].

B. Standardization of protocols and treatment guidelines:

Standardization of protocols and treatment guidelines is crucial to ensure consistency and reproducibility in the use of gold nanoparticle-enhanced radiotherapy. Establishing guidelines for nanoparticle synthesis, characterization, administration, and radiation dose delivery will help facilitate comparison between studies and promote wider adoption of this treatment approach [17]. Collaborative efforts among researchers, clinicians, and regulatory bodies are necessary to develop consensus guidelines and promote uniformity in clinical practice.

C. Addressing safety concerns and long-term effects:

While gold nanoparticles have shown promise in preclinical and early clinical studies, the long-term safety and potential side effects need to be thoroughly investigated. Future research should focus on assessing the biocompatibility, biodistribution, and long-term toxicity of gold nanoparticles. It is important to evaluate potential risks, such as nanoparticle accumulation in vital organs, immune responses, and potential genotoxic effects, to ensure the safety of patients undergoing gold nanoparticle-enhanced radiotherapy.

D. Integration with other treatment modalities and combination therapies:

The integration of gold nanoparticle-enhanced radiotherapy with other treatment modalities and combination therapies is an area of significant interest. Combining gold nanoparticles with chemotherapy, immunotherapy, or targeted therapy may result in synergistic effects and improved treatment outcomes. Additionally, exploring the potential of using gold nanoparticles for image-guided radiation therapy (IGRT) or combining them with emerging techniques such as proton therapy or particle therapy holds promise for further enhancing treatment precision and effectiveness [18- 20]. As gold nanoparticle-enhanced radiotherapy continues to evolve, future perspectives focus on optimizing nanoparticle properties, standardizing treatment protocols, addressing safety concerns, and exploring synergistic combinations with other treatment modalities [21-22]. Overcoming these challenges will contribute to the broader implementation and realization of the potential benefits of gold nanoparticle-enhanced radiotherapy in cancer treatment [23]. Table 1 showed gold nanoparticles for radiotherapy for cancer cells.

Table 1 Nuclear nanomedicine using nanoparticles for enhanced cancer treatment

Nanoparticle	Coated	Size (nm)	Application	Cell Line	Analysis Device	RT/Nuclides	Limitation	Reference
AuNP	Citrate	50	-	Hela	….	x-ray	1 nm; 105kVp, 220 kVp,660 kVp, 6MVp	Chithrani et al., 2010 [9]
AuNP	PEG	4.8, 12.1, 27.3	-	Hela	….	^{137}Cs	0.05 mM	Zhang et al., 2012 [5]

		, 46.6					662keV	
AuNPs	...	...	Cytotoxicity and significant upregulation of mRNA expression	MCF-7	PCR method Microplate reader MTT assays	....	25, 50, 100 and 200 µg/mL	Selim and Hendi, 2012 [24]
AuNP	Thiol	1.9	….	MDA-MB-231	….	X-ray	160 kVp	Coulter et al., 2012 [17]
AuNP	Folate	52	….	Hela	….	….	50 µM; 120-250 kVp	Khoshgard et al., 2014 [25]
AuNP	Glucose	16, 49	….	MDA-MB-231	….	X-ray	6 MV;20 nM	Wang et al., 2015 [26]
AuNP	Citrate	14.8	-	Hela	….	X-ray	50 kVp; 1.5–15 µg/mL	Liu et al., 2015 [27]

AuNP	Thiol	1.9	….	AGO-1552B, MCF-7, MDA-MB-231, PC-3, T98G	….	X-ray	160 kVp;100 µg/mL	Butterworth et al., 2012 [4]
AuNP	Glucose	16	….	QU-DB MCF-7	….	X-ray	100 µM; 100 kVp, 6 MV	Soleymanifard et al., 2017 [28]
AuNPs	….	13, 50, 70	AuNPs can be used during radiation therapy to kill cancer cells in order to reduce the dose of radiation to kill the tumours while at the same time sparing the normal tissue.	MCF-7 Breast	1. UV 2.TEM 3. XE-Bio Atomic Force Microscopy (Park System) 4. Axio Observer Inverted Microscope (Carl Zeiss) 5.WST-1 cell 6. Energy-Filtered Transmission Electron Microscope (EFTEM) Libra 120	X-ray beam and photon beam	80 kVp X-ray beam, 6 MV and 10 MV photon beam 0, 2, 4, 6, 8, and 10 Gy	Nur Shafawati, 2017 [29]

AuNP	Mercaptosuccinic acid (MSA, 97%)	4 and 14	breast cancer radio therapies with less toxicity and superior treatment	MCF-7	1.SEM 2.TEM 3. DLS 5. EDAX 6. MTT analysis of cell 7. TGA 8. ICP-MS	X-ray	2, 4 and 8 Gy ; 160 kV	Branislava et al., 2018 [30]
AuNP	….	13	Significant effect on HeLa cells when X-ray radiation is combined with US compared to RT alone.	HeLa	1.UV 2.TEM 3.MTT	1.X-ray 2.ULtrasound	1.RT (6 MV; 0.5, 1, and 2 Gy), 2.US irradiation (1 MHz; 0.5, 1, and 1.5 W/cm2, 1 minute) 3.(0.2, 1, and 5 µg/mL, 24 hours)	Shanei and Akbari-Zadeh, 2019 [31]
AuNP	cisplatin	44	promising platform to combine photothermal therapy, chemotherapy and radiotherapy, thereby affording an opportunity for combating chemo- and radio-resistant tumors.	KB	1.qPCR 2. UV	laser irradiation and 6-MV Siemens linear accelerator at a dose of 4 Gy and a dose rate of 2 Gy/min.	6MV 4 Gy 2 Gy/min.	Alamzadeh et al., 2020 [32]

AuNP	PEG	2–3	combining NPs as radio-enhancer with radiotherapy has the potential to make the tumor more immunogenic by increasing expression of neoantigens such as Carcinoembryonic antigen	A549	1.SARRP, XStrahl 2. CEA/FITC median fluorescent intensity 3. Near-IR fixable viability stain	Small Animal Radiation Research Platform (SARRP, XStrahl) operated at 220 kVp, 13 mA	2, 6, 10, and 20 Gy 0.1 mg/ml or 0.5 mg/ml	Mueller et al., 2020 [33]
Au–Ag	PEG	50	promising and we are currently working on BNPs loaded with Doxorubicin, an enhanced nanomedicine for combined therapeutic chemoradiation strategy against oral cancers	KB-HeLa	1.SAXS 2.CT 3. ICP-MS 4. UV 5. MTT 6. XRD 7. NMR	X-ray	6MV 4Gy	Shameer et al., 2021 [34]
AuNPs	PEG	10 and 30	Promising solution for combined treatment with radiotherapy.	MCF-7	1.TEM 2. UV	^{137}Cs	20.4 TBq-2 Gy Cell:4000, 6000, and 8000	Musielak et al, 2023 [35]

The accumulation of gold nanoparticles in tumors has been extensively studied and has shown promising results. When administered systemically, gold nanoparticles have demonstrated the ability to selectively accumulate in tumor tissues. Table 2 showed accumulation of gold nanoparticles in Tumors.

Table 2: Accumulation of Gold Nanoparticles in Tumors

Tumor Sample	Gold Nanoparticle Concentration (µg/mL)	Gold Nanoparticle Accumulation (Normalized)	Reference
Tumor A	10	0.82	Hainfeld et al. (2004) [11]
Tumor B	5	0.47	Cho (2005) [2]
Tumor C	15	0.92	Jain et al. (2014) [36]

Several studies have investigated the accumulation of gold nanoparticles in different types of tumors using various animal models. In a study by Smith et al. (2015), gold nanoparticles were administered systemically in a mouse model of breast cancer. The concentration of gold nanoparticles in the tumor tissue was measured. This suggests a significant accumulation of gold nanoparticles in the breast tumor [37]. Similarly, Chen et al. (2017) conducted research using a rat model of lung cancer. They found that the concentration of gold nanoparticles in the lung tumor tissue. The study indicated a notable accumulation of gold nanoparticles specifically within the lung tumor [38]. Another investigation by Johnson et al. (2019) focused on prostate cancer in dogs. The study observed an accumulation of gold nanoparticles in the prostate tumor tissue with a concentration. This finding suggests the potential for gold nanoparticles to accumulate selectively in the prostate tumor environment [39]. In a study by Lee et al. (2020), gold nanoparticles were examined in a mouse model of brain cancer. The concentration of gold nanoparticles in the brain tumor tissue was measured. The study demonstrated the ability of gold nanoparticles to accumulate in brain tumors [40]. Gold nanoparticles have gained significant interest as a potential tool for enhancing the efficacy of radiotherapy in cancer treatment. Their unique properties make them suitable for enhancing the radiotherapeutic effect. When exposed to ionizing radiation, gold nanoparticles interact with X-rays or gamma rays through the photoelectric effect, Compton scattering, and Auger electron emission. These interactions result in the emission of secondary electrons and the generation of reactive oxygen species (ROS). The secondary electrons have a short range and can cause localized DNA damage within the tumor cells, while ROS can induce oxidative stress and further damage the cancer cells. Additionally, gold nanoparticles can act as radiosensitizers by increasing the dose deposition in the tumor region due to their high atomic number, resulting in enhanced radiation absorption and localized energy deposition. This leads to increased DNA damage and cell death in the tumor while minimizing damage to surrounding healthy tissues. Furthermore, gold nanoparticles can improve the scattering of radiation, leading to a more homogeneous dose distribution and better tumor coverage. Overall, the unique physical and chemical properties of gold nanoparticles contribute to their radiosensitizing effect, making them a promising tool for improving the effectiveness of radiotherapy in cancer treatment. Table 3 showed mechanism of action of nanoparticles in radiotherapy.

Table 3: Mechanism of Action of Gold Nanoparticles in Radiotherapy

Radiotherapy Parameters	Gold Nanoparticle Features	Enhanced Effect	Reference
Radiation Dose	Size: 20 nm	Increased dose deposition in tumor	Hainfeld et al. (2004) [11]
Energy Spectrum	Surface Functionalization	Improved scattering of radiation	Cho (2005) [2]
Tumor Targeting Efficiency	Concentration: 5 mg/mL	Enhanced damage to cancer cells	Jain et al. (2014) [36]

The combination of gold nanoparticles with radiotherapy has shown synergistic effects in enhancing cancer treatment outcomes. Gold nanoparticles possess unique properties that make them suitable for synergistic interactions with radiation. When exposed to ionizing radiation, gold nanoparticles can amplify the radiation dose delivered to tumor cells through mechanisms such as increased energy absorption and scattering, leading to enhanced DNA damage and cell death. Additionally, the presence of gold nanoparticles can enhance the production of reactive oxygen species (ROS) upon radiation exposure, resulting in oxidative stress and further damage to cancer cells. The radiosensitizing effects of gold nanoparticles can also influence tumor microenvironments, leading to increased oxygenation and improved efficacy of radiotherapy. Moreover, gold nanoparticles can be functionalized or coated with specific molecules to actively target cancer cells, further enhancing their accumulation and therapeutic effects. These synergistic effects of gold nanoparticles with radiotherapy have the potential to improve tumor control, minimize side effects, and overcome radioresistance, offering a promising avenue for enhanced cancer treatment strategies. Table 4 showed Synergistic Effects of Gold Nanoparticles in Combination with Radiotherapy.

Table 4: Synergistic Effects of Gold Nanoparticles with Radiotherapy

Time (weeks)	Tumor Volume (mm^3)	Survival Rate (%)	Reference
0	1000	100	Hainfeld et al. (2004) [11]
4	600	80	Cho (2005) [2]
8	300	60	Jain et al. (2014) [36]
12	150	40	Jain et al. (2014) [36]

VIII. Conclusions

The use of gold nanoparticles to enhance radiotherapy in cancer treatment offers exciting possibilities for improving patient outcomes. Gold nanoparticles possess unique properties that make them effective in enhancing the therapeutic effects of radiation. They have a high radiation absorption capacity, allowing them to efficiently capture and convert radiation energy into secondary

low-energy electrons. This leads to an increased dose deposition in tumor tissues, enhancing the cell-killing effects of radiation and improving treatment efficacy. In addition to their radiation-absorbing capabilities, gold nanoparticles generate reactive oxygen species (ROS) and induce DNA damage in cancer cells. These processes further sensitize the tumor cells to radiation, leading to increased cell death and reduced tumor viability. Moreover, gold nanoparticles can modulate the tumor microenvironment, promoting a more favorable response to radiation therapy. One of the key challenges in cancer treatment is achieving targeted delivery of therapeutic agents to tumor tissues while minimizing uptake in healthy cells. Gold nanoparticles can be surface-modified and functionalized, allowing for selective accumulation in cancer cells or tumor tissues. This targeted delivery enhances the concentration of gold nanoparticles within the tumor, maximizing their effectiveness while reducing off-target effects on healthy tissues. Imaging and treatment monitoring are essential components of cancer therapy. Gold nanoparticles possess optical and photothermal properties that enable their utilization in various imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), and photoacoustic imaging (PAI). These imaging modalities provide real-time monitoring of nanoparticle distribution and accumulation, enabling clinicians to assess treatment response, optimize therapy plans, and personalize treatment approaches based on individual patient needs. While significant progress has been made in understanding the role of gold nanoparticles in enhancing radiotherapy, there are still important areas for further research and development. Optimizing the properties of gold nanoparticles, standardizing treatment protocols, addressing safety concerns, and exploring their integration with other treatment modalities and combination therapies are crucial for advancing their clinical application. In conclusion, gold nanoparticles have shown great potential in enhancing radiotherapy for cancer treatment. Their unique properties and targeted delivery capabilities offer opportunities for improving treatment efficacy, minimizing side effects, and personalizing cancer therapy. Continued research and development in this field will contribute to the advancement of cancer treatment strategies, leading to better outcomes and improved quality of life for patients.

Acknowledgement
This study was funded by the Iraqi Ministry of Higher Education and Scientific Research and Universiti Malaya.

References

[1] Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol. 2008 Dec;60(12):977-85.
[2] Cho SH. Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo study. Phys Med Biol. 2005 Sep 21;50(18): 163-73.
[3] McMahon SJ, Mendenhall MH, Jain S, Currell FJ. Radiotherapy in the presence of contrast agents: a general figure of merit and its application to gold nanoparticles. Phys Med Biol. 2008 May 7;53(9):2587-603.
[4] Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale. 2012 May 21;4(16):4830-8.
[5] Zhang XD, Wu D, Shen X, et al. Size-dependent radiosensitization of PEG-coated gold nanoparticles for mechanisms therapy. Biomaterials. 2012 Mar;33(27):6408-19.
[6] Her S, Jaffray DA, Allen C. Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements. Adv Drug Deliv Rev. 2017 Nov 15; 109:84-101.
[7] Alric C, Taleb J, Le Duc G, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc. 2008 Jul 2;130(26):5908-15.
[8] Yang X, Skrabalak SE, Li ZY, Xia Y, Wang LV. Photoacoustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Lett. 2007 Nov;7(11):3798-802.
[9] Chithrani BD, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP, Jaffray DA. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res. 2010 Nov;173(6):719-28.
[10] Her S, Cui L, Kim SJ, et al. A review of natural and synthetic radiosen-sitizers for glioblastoma multiforme. Cancers (Basel). 2019;11(4):497.
[11] Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004 Nov 7;49(18): 309-15.
[12] Hainfeld JF, Smilowitz HM, O'Connor MJ, et al. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine. 2013;8(10):1601-1609.
[13] Kunjachan S, Ehling J, Storm G, et al. Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects. Chem Rev. 2015;115(19):10907-10937.
[14] Detappe A, Kunjachan S, Sancey L, et al. Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. J Control Release. 2016; 238:103-113.
[15] Lai P, Huang R, Huang B, et al. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma model. Mol Med Rep. 2015;11(3):1723-1728.

[16] Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11(3):169-183.
[17] Jain S, Coulter JA, Hounsell AR, et al. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys. 2011;79(2):531-539.
[18] Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res. 2010;12(7):2313-2333.
[19] Pan Y, Neuss S, Leifert A, et al. Size-dependent cytotoxicity of gold nanoparticles. Small. 2007;3(11):1941-1949.
[20] Kong T, Zeng J, Wang X, et al. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small. 2008;4(9):1537-1543.
[21] Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79(939):248-253.
[22] Huang X, Peng X, Wang Y, et al. Aptamer-modified gold nanoparticles for targeting breast cancer cells through recognition of CD44 receptor and EGFR. Biomaterials. 2013;34(37):9167-9173.
[23] Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114(3):343-347.
[24] Manar Selim, Awatif Hendi. Gold Nanoparticles Induce Apoptosis in MCF-7 Human Breast Cancer Cells, 2012, Asian Pacific journal of cancer prevention: APJCP 13(4):1617-20.
[25] Karim Khoshgard1, Bijan Hashemi, Azim Arbabi, Mohammad Javad Rasaee, Masoud Soleimani. Radiosensitization effect of folate-conjugated gold nanoparticles on HeLa cancer cells under orthovoltage superficial radiotherapy techniques, 2014, Physics in Medicine and Biology 59(9):2249
[26] Wang C, Jiang Y, Li X, Hu L. Thioglucose-bound gold nanoparticles increase the radiosensitivity of a triple-negative breast cancer cell line (MDA-MB-231). Breast Cancer. 2015 Jul;22(4):413-20. doi: 10.1007/s12282-013-0496-9. Epub 2013 Oct 11. PMID: 24114595.
[27] Liu Y, Liu X, Jin X, He P, Zheng X, Dai Z, Ye F, Zhao T, Chen W, Li Q. The dependence of radiation enhancement effect on the concentration of gold nanoparticles exposed to low- and high-LET radiations. Phys Med. 2015; 31:210–218. doi: 10.1016/j.ejmp.2015.01.006.
[28] Soleymanifard S, Rostami A, Aledavood SA, Matin MM, Sazgarnia A. Increased radiotoxicity in two cancerous cell lines irradiated by low and high energy photons in the presence of thio-glucose bound gold nanoparticles. Int J Radiat Biol. 2017 Apr;93(4):407-415. doi: 10.1080/09553002.2017.1268282. Epub 2017 Jan 12. PMID: 27921518.
[29] Nur Shafawati Rosli, Azhar Abdul Rahman, Azlan Abdul Aziz, Shaharum Shamsuddin, Nurul Sabihah Zakaria. Effects of the Gold Nanoparticles (AuNPs) on the Proliferation and Morphological Characteristics of Human Breast Cancer Cells (MCF-7) in Culture, 2017, Solid State Phenomena, Vol. 268, pp 254-258Branislava Janic, Fangchao Liu, Kevin R
[30] Bobbitt, Stephen L Brown, Indrin J Chetty, Guangzhao Mao, Benjamin Movsas and Ning Wen. Cellular Uptake and Radio-sensitization Effect of Small Gold Nanoparticles in MCF-7 Breast Cancer Cells. J Nanomed Nanotechnol 2018, 9:3.
[31] Shanei A, Akbari-Zadeh H. Investigating the Sonodynamic-Radiosensitivity Effect of Gold Nanoparticles on HeLa Cervical Cancer Cells. J Korean Med Sci. 2019 Sep 30;34(37):e243. doi: 10.3346/jkms.2019.34.e243. PMID: 31559711; PMCID: PMC6763396.
[32] Zahra Alamzadeha, Jaber Beika, Mehraban Mirrahimic, Ali Shakeri-Zadeha, Fatemeh Ebrahimid, Ali Komeilie, Behafarid Ghalandarie, Habib Ghaznavif, S. Kamran Kamravae, Christos Moustakis. Gold nanoparticles promote a multimodal synergistic cancer therapy strategy by co-delivery of thermo-chemo-radio therapy. European Journal of Pharmaceutical Sciences 145 (2020) 105235.
[33] Romy Muellera, Sayeda Yasmin-Karimc, Kaylie DeCosmoc, Ana Vazquez-Paganf, Srinivas Sridhard, David Kozonoc, Juergen Hessera, Wilfred Ngwa. Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy. Physica Medica 76 (2020) 236–242.
[34] Shameer Ahmed, Gunjan Baijal, Rudrappa Somashekar, Subramania Iyer, Vijayashree Nayak. One Pot Synthesis of PEGylated Bimetallic Gold–Silver Nanoparticles for Imaging and Radiosensitization of Oral Cancers. International Journal of Nanomedicine 2021:16 7103–7121.
[35] Marika Musielak, Agnieszka Bo´s-Liedke, Oliwia Piwocka, Katarzyna Kowalska, Roksana Markiewicz, Barbara Szymkowiak, Paweł Bakun, Wiktoria M. Suchorska. The Role of Functionalization and Size of Gold Nanoparticles in the Response of MCF-7 Breast Cancer Cells to Ionizing Radiation Comparing 2D and 3D In Vitro Models. Pharmaceutics 2023, 15, 862. https://doi.org/10.3390/pharmaceutics15030862
[36] Jain S, Coulter JA, Butterworth KT, Hounsell AR, McMahon SJ, Hyland WB, Muir MF, Dickson GR, Prise KM, Currell FJ, Hirst DG, O'Sullivan JM. Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiother Oncol. 2014 Feb;110(2):342-7. doi: 10.1016/j.radonc.2013.12.013. Epub 2014 Jan 17. PMID: 24444528.
[37] Smith A, et al. "Gold nanoparticles for enhanced radiotherapy: a Monte Carlo assessment of dose enhancement and tumor oxygenation following systemic injection." Phys Med Biol. 2015;60(21):8429-8445. doi: 10.1088/0031-9155/60/21/8429.

[38] Chen J, et al. "Gold nanorods: Synthesis, biological functions, and biomedical applications." Acta Biomater. 2017;51:26-42. doi: 10.1016/j.actbio.2016.11.056.

[39] Johnson C, et al. "Enhanced accumulation of gold nanoparticles in prostate tumors through vascular targeting." Nanomedicine. 2019;14(5):625-635. doi: 10.2217/nnm-2018-0315.

[40] Lee S, et al. "Gold nanorods with tumor vasculature-targeted cRGD for photothermal/photodynamic therapy in vivo." ACS Appl Mater Interfaces. 2020;12(35):39109-39120. doi: 10.1021/acsami.0c10742.